Pravastatin

• High cholesterol (hyperlipidemia)
• Cardiovascular disease prevention
• Coronary artery disease - secondary prevention
• Mixed dyslipidemia
• High triglycerides (hypertriglyceridemia)
• Slowing atherosclerosis progression

Pravastatin (Pravachol) is a moderate-intensity HMG-CoA reductase inhibitor used to lower LDL cholesterol and reduce the risk of cardiovascular events including myocardial infarction, stroke, coronary revascularization, and cardiovascular death. Among the statin class, it is distinguished by being hydrophilic, minimally metabolized through the cytochrome P450 system, and predominantly cleared by the liver via active uptake and biliary excretion. Those properties translate into one of the cleanest drug-interaction profiles in the class, making pravastatin a frequent choice for patients on complex medication regimens — particularly those receiving immunosuppressants, antiretrovirals, calcium channel blockers, or amiodarone — where higher-intensity options like simvastatin or atorvastatin raise concern.

Mechanism of Action

Pravastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate in the hepatic cholesterol biosynthesis pathway. The reduction in intracellular cholesterol stimulates upregulation of hepatic LDL receptors, which then clear LDL particles more aggressively from the bloodstream. The net effect is a 25 to 35 percent reduction in serum LDL cholesterol at typical doses, modest 10 to 15 percent reductions in triglycerides, and small increases in HDL cholesterol of roughly 3 to 7 percent.

Beyond LDL lowering, statins exert pleiotropic effects that contribute to their cardiovascular benefit. These include reduced vascular inflammation (measurable as lower high-sensitivity C-reactive protein), improved endothelial function via increased nitric oxide bioavailability, plaque stabilization through changes in macrophage and smooth muscle behavior, and antithrombotic effects on platelets and the coagulation cascade. The clinical relevance is substantial: in trials such as WOSCOPS, CARE, and LIPID, pravastatin reduced major coronary events by 24 to 31 percent across primary and secondary prevention populations, with benefits emerging within the first year and persisting throughout follow-up. The American Heart Association cholesterol resource provides patient-level context on these outcomes.

Clinical Use

Pravastatin is a reasonable choice for primary prevention in adults with elevated 10-year atherosclerotic cardiovascular disease (ASCVD) risk, for hypercholesterolemia, mixed hyperlipidemia, and for secondary prevention in patients with established coronary artery disease, prior stroke, or peripheral artery disease. Within the algorithm, the 2018 ACC/AHA cholesterol guideline categorizes pravastatin 40 to 80 mg as moderate-intensity therapy, with expected LDL reductions of 30 to 49 percent. For patients requiring high-intensity therapy (LDL reduction of 50 percent or more), atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg are preferred.

Patient selection that favors pravastatin includes prior statin intolerance with another agent, concurrent use of strong CYP3A4 inhibitors, organ transplant recipients on cyclosporine or tacrolimus (with appropriate dose limitation), and elderly patients in whom drug interaction simplification reduces overall medication risk. Comparative effectiveness data show smaller LDL reductions than atorvastatin and rosuvastatin at maximum doses, but similar event-prevention efficacy when properly dosed for risk category. For families seeking primer-level material, the understanding cholesterol article and the statins guide provide accessible context. Our cardiovascular team coordinates lipid management with broader risk reduction including blood pressure, diabetes care, smoking cessation, and exercise prescription. For patients who do not reach LDL targets on maximum-tolerated statin therapy, ezetimibe and the PCSK9 inhibitor class are the next steps and have largely replaced bile acid sequestrants in modern algorithms. Patients with established atherosclerotic disease and persistent LDL above 70 mg/dL despite high-intensity statin therapy are particularly likely to benefit from add-on therapy. Lifestyle counseling — Mediterranean-style diet, at least 150 minutes of moderate aerobic activity per week, weight management, and sleep optimization — should accompany every statin prescription because medication is most effective layered onto a healthy foundation.

How to Take It

Take pravastatin once daily at any time of day, with or without food. Unlike short-acting statins such as simvastatin, pravastatin has a relatively long inhibitory effect at the hepatic enzyme level, so timing flexibility is real — many patients take it in the morning, others at bedtime. Consistency matters more than time of day. Tablets are 10, 20, 40, and 80 mg; the typical starting dose is 40 mg in adults, with titration to 80 mg if LDL goals are not met. If a dose is missed and it is still the same day, take it; if a full day has passed, skip and resume — do not double up.

Avoid grapefruit juice in large quantities as a general statin precaution, though pravastatin is far less affected than CYP3A4-metabolized statins. Bile acid sequestrants such as cholestyramine or colestipol significantly reduce pravastatin absorption; separate doses by at least 4 hours, with pravastatin taken first or at bedtime. The first 2 to 4 weeks may bring mild gastrointestinal upset, occasional myalgia, or headache, most of which resolve. Keep all routine vaccines and discuss any new medications with the prescriber before starting them.

Monitoring and Follow-Up

Baseline labs include a fasting lipid panel, comprehensive metabolic panel for liver enzymes (ALT and AST), creatine kinase if there is preexisting muscle complaint or risk factor, TSH if not recently checked, and hemoglobin A1c. Recheck the lipid panel at 4 to 12 weeks after initiation and after any dose change to assess response. The expected LDL reduction at 40 mg is roughly 30 to 35 percent; if the patient is short of the target reduction by 15 percent or more, adherence and lifestyle should be revisited before titration. Once stable, lipids are checked every 6 to 12 months along with ALT. Adherence is the single largest determinant of statin success in real-world practice; roughly half of patients have stopped statin therapy within a year of initiation, often without telling their prescriber. Open conversations about side effects, dosing schedules, and medication cost help identify and address barriers before they become persistent.

ALT or AST elevations above 3 times the upper limit of normal warrant investigation and possible discontinuation; mild transient elevations under that threshold are common and rarely require action. Routine creatine kinase monitoring is not recommended; check CK only with new muscle symptoms, in which case discontinuation and reassessment are appropriate if values exceed 5 to 10 times the upper limit of normal. Hemoglobin A1c rises slightly on statins (around 0.1 to 0.3 percent on average) and may unmask new diabetes in high-risk patients; treat the diabetes and continue the statin because cardiovascular benefits exceed the metabolic risk. The U.S. Preventive Services Task Force statin recommendation outlines population-level rationale.

Special Populations

Pravastatin is contraindicated in pregnancy and lactation; women of reproductive potential should use effective contraception. The 2021 FDA label change removed the broad contraindication and now allows individualized decision-making in pregnancy for highest-risk women, but most clinicians still discontinue at conception. Pediatric dosing applies to ages 8 and older with familial hypercholesterolemia: 20 mg daily for ages 8 to 13 and 40 mg daily for ages 14 to 18. Elderly patients tolerate pravastatin well; no routine dose adjustment is needed but baseline myalgia screening is helpful. Significant renal impairment with eGFR below 30 mL/min calls for starting at 10 mg daily and titrating cautiously. Active liver disease or unexplained persistent transaminase elevation is a contraindication. Cyclosporine markedly increases pravastatin levels; the dose must be capped at 20 mg daily in transplant recipients on cyclosporine.

When to Contact Your Doctor

Call promptly for new severe muscle pain, weakness, or tenderness — especially if accompanied by fever, dark cola-colored urine, or generalized malaise — because these can signal rhabdomyolysis, a rare but serious complication. Yellowing of the skin or eyes, persistent right upper quadrant abdominal pain, dark urine, or unusual fatigue with nausea may indicate hepatotoxicity and warrant prompt liver function testing. Confusion or memory problems should be discussed; statin-associated cognitive symptoms are uncommon and usually reversible. Any rash, hives, swelling of the face or tongue, or trouble breathing is an allergic reaction warning sign. Discuss any planned new medication, particularly antibiotics, antifungals, antivirals, or rate-control drugs, before starting them.

If cholesterol management or cardiovascular risk reduction is a priority, contact us or schedule a visit so our team can review your lipid panel, calculate your 10-year risk, and decide whether pravastatin or another statin best fits your situation.